{"id":63825,"date":"2023-04-27T07:00:00","date_gmt":"2023-04-27T05:00:00","guid":{"rendered":"https:\/\/d14saept1n0koz.cloudfront.net\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/"},"modified":"2023-04-27T07:00:00","modified_gmt":"2023-04-27T05:00:00","slug":"ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830","status":"publish","type":"press_release","link":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/","title":{"rendered":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&rsquo;exercice 2023"},"content":{"rendered":"<p><strong>Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&rsquo;exercice 2023<\/strong><\/p>\n<p align=\"justify\"><strong>Paris (France), 27 avril 2023<\/strong><br \/>Ipsen (Euronext: IPN; ADR: IPSEY), Groupe biopharmaceutique mondial focalis\u00e9 sur la M\u00e9dicine de Sp\u00e9cialit\u00e9, publie aujourd\u2019hui son chiffre d\u2019affaires pour le premier trimestre 2023.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:20.15%;vertical-align: middle\">    \u00a0<\/p>\n<p>        \u00a0    <\/td>\n<td style=\"width:1.03%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"width:14.4%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:1.03%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"width:7.19%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>1<\/strong><\/sup>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;border-bottom: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1.03%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.19%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Oncologie     <\/td>\n<td style=\"width:1.03%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    570,8    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    556,4    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,6%    <\/td>\n<td style=\"width:7.19%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,1%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Neurosciences    <\/td>\n<td style=\"width:1.03%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    156,4    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    120,2    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    30,2%    <\/td>\n<td style=\"width:7.19%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    24,4%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Maladies\u00a0Rares    <\/td>\n<td style=\"width:1.03%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    14,7    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    11,3    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    29,8%    <\/td>\n<td style=\"width:7.19%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    29,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Chiffre d\u2019affaires Groupe<\/strong><sup><strong>2<\/strong><\/sup>    <\/td>\n<td style=\"width:1.03%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>741,9<\/strong>    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>687,9<\/strong>    <\/td>\n<td style=\"width:7.21%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>7,8%<\/strong>    <\/td>\n<td style=\"width:7.19%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,7%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.15%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1.03%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.21%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.19%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<\/tr>\n<\/table>\n<p><strong>Faits marquants<\/strong><\/p>\n<ul>\n<li>Croissance des ventes de 5,7% \u00e0 taux de change constant<sup>1<\/sup>, ou de 7,8% en donn\u00e9es publi\u00e9es, tir\u00e9e par les performances des plateformes de croissance<sup>3<\/sup>, en hausse de 14,7%<sup>1<\/sup>, avec une augmentation de 25,2%<sup>1<\/sup> pour Dysport<sup>\u00ae<\/sup> (abobotulinumtoxinA) et de 31,0%<sup>1<\/sup> pour Cabometyx<sup>\u00ae<\/sup> (cabozantinib). Contribution des produits r\u00e9cemment acquis Tazverik<sup>\u00ae<\/sup> (tazemetostat) et Bylvay<sup>\u00ae<\/sup> (odevixibat) \u00e0 la performance des ventes.\n<\/li>\n<li>Finalisation de l&rsquo;accord de fusion d\u00e9finitif d\u2019acquisition d\u2019Albireo, renfor\u00e7ant la pr\u00e9sence du Groupe dans les Maladies Rares.\n<\/li>\n<li>Confirmation des dates par les autorit\u00e9s r\u00e9glementaires am\u00e9ricaines pour statuer sur l\u2019approbation de Bylvay dans le syndrome d&rsquo;Alagille et du palovarot\u00e8ne dans la fibrodysplasie ossifiante progressive (FOP).\n<\/li>\n<li>Confirmation des objectifs financiers annuels pour l\u2019exercice 2023, avec une croissance du chiffre d\u2019affaires Groupe sup\u00e9rieure \u00e0 4,0% \u00e0 taux de change constant<sup>1<\/sup> et une marge op\u00e9rationnelle des activit\u00e9s d&rsquo;environ 30% du chiffre d\u2019affaires Groupe.<\/li>\n<\/ul>\n<p align=\"justify\"><strong>David Loew, Directeur g\u00e9n\u00e9ral d\u2019Ipsen, a d\u00e9clar\u00e9\u00a0: <\/strong><br \/>\u00ab Ipsen continue de faire d\u2019excellents progr\u00e8s dans son plan de transformation. Nous affichons une solide croissance de nos ventes au premier trimestre, port\u00e9es par les excellentes performances du Dysport et Cabometyx. Compte tenu de la bonne dynamique des ventes, nous confirmons nos objectifs financiers pour l&rsquo;ensemble de l&rsquo;exercice 2023. Je me r\u00e9jouis \u00e9galement de voir s&rsquo;\u00e9toffer notre portefeuille de R&amp;D, notre portefeuille de produits commercialis\u00e9s et nos \u00e9quipes \u00e0 la suite de la r\u00e9cente acquisition d&rsquo;Albireo. Gr\u00e2ce \u00e0 notre pr\u00e9sence mondiale, Ipsen continuera de r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits d&rsquo;un nombre croissant de patients. Alors que nous renfor\u00e7ons notre portefeuille de produits en R&amp;D et nous int\u00e9grons nos r\u00e9centes acquisitions, nous anticipons plusieurs \u00e9tapes importantes, telles que les r\u00e9sultats de Phase III pour elafibranor et des nouvelles avanc\u00e9es r\u00e9glementaires anticip\u00e9es pour Onivyde, palovarot\u00e8ne et Bylvay\u00a0\u00bb<\/p>\n<p align=\"justify\"><strong>Objectifs financiers pour 2023<\/strong><br \/>Ipsen a confirm\u00e9 ses objectifs financiers pour l\u2019exercice 2023<sup>4<\/sup>\u00a0:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Croissance du chiffre d\u2019affaires Groupe sup\u00e9rieure \u00e0 4,0%, \u00e0 taux de change constants. Sur la base des taux de change moyens du premier trimestre 2023, Ipsen anticipe un impact d\u00e9favorable des devises de l\u2019ordre de 2% sur le chiffre d\u2019affaires Groupe.\n<\/li>\n<li style=\"text-align:justify\">Marge op\u00e9rationnelle des activit\u00e9s d&rsquo;environ 30\u00a0% du chiffre d\u2019affaires Groupe, hors impact potentiel\u00a0d&rsquo;investissements\u00a0additionnels dans le cadre de l&rsquo;innovation externe.<\/li>\n<\/ul>\n<p><strong>Business D\u00e9veloppement<\/strong><\/p>\n<p align=\"justify\">En mars 2023, Ipsen a annonc\u00e9 avoir finalis\u00e9 l&rsquo;acquisition d\u2019Albireo\u00a0Pharma,\u00a0Inc., une entreprise innovante de premier plan dans le domaine des modulateurs d\u2019acides biliaires pour le traitement des maladies h\u00e9patiques rares. Ipsen a acquis toutes les actions \u00e9mises et en circulation d\u2019Albireo au prix de 42,00\u00a0$ par action en num\u00e9raire, auquel s\u2019ajoute un Certificat de Valeur Garantie (CVG) non transf\u00e9rable de 10,00\u00a0$ par action. <\/p>\n<p><strong>D\u00e9veloppement du portefeuille de produits en R&amp;D<\/strong><\/p>\n<p align=\"justify\">En f\u00e9vrier 2023, Ipsen a annonc\u00e9 que les autorit\u00e9s am\u00e9ricaines (Food and Drug Administration) ont accept\u00e9 la nouvelle demande d&rsquo;approbation de Bylvay dans le cadre d&rsquo;une deuxi\u00e8me indication chez les patients atteints du syndrome d&rsquo;Alagille. La FDA a \u00e9galement communiqu\u00e9 une date butoir en vertu de la loi am\u00e9ricaine Prescription Drug User Fee Act (PDUFA), le 15 juin 2023.<\/p>\n<p align=\"justify\">En mars 2023, Ipsen a annonc\u00e9 que les autorit\u00e9s r\u00e9glementaires am\u00e9ricaines (FDA) ont communiqu\u00e9 une nouvelle date au titre du PDUFA, le 16 ao\u00fbt 2023, pour r\u00e9pondre \u00e0 la nouvelle demande d\u2019approbation du palovarot\u00e8ne comme traitement potentiel de la fibrodysplasie ossifiante progressive (FOP). Le Groupe a \u00e9galement r\u00e9cemment demand\u00e9 au CHMP<sup>5<\/sup> de r\u00e9examiner sa position communiqu\u00e9e en janvier 2023 sur le palovarot\u00e8ne.<\/p>\n<p align=\"justify\"><strong>Conf\u00e9rence t\u00e9l\u00e9phonique (en anglais)<\/strong><br \/>Une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast destin\u00e9s aux investisseurs et analystes se tiendront aujourd\u2019hui \u00e0 14h, heure de Paris. Les participants peuvent acc\u00e9der \u00e0 la conf\u00e9rence et aux informations correspondantes via ce <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GGiuNmU4ezXqJ3mviNYDw7dyKLPJ5ayIczUNThDLOAW0SV8icoTKyGlse_9Hm4aW_7lcgoM_sGHAMW1GnCXjnYHlt2qOUWhliIN-mv4rsyNnPmChZ-llRfdBYoM8h1U9cYsbmpy1bo1FtOm2hZeEXQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>lien<\/u><\/a>. Pour en savoir plus sur le webcast, toutes les informations n\u00e9cessaires sont disponibles <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FoIscmDdiJBjlWHoeXKQldBR5gdmopp_6dhGdfXuiQ1h5nkKs8euXnY5XFfDaeLJ_A0ellCA0GM0Eq73Q6dXXg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>ici<\/u><\/a>. Un enregistrement sera disponible sur le site Internet <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fgufRHPnuX0l01TcuZ4pir1bB0vnhx3XwJ27nGvaRgLz2CoOVUaSWJUvwO8EMgK-bYk-5C_XJNrWYNTYoVQJgg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>ipsen.com<\/u><\/a>. <\/p>\n<p align=\"justify\"><strong>Calendrier<\/strong><br \/>Ipsen pr\u00e9voit de publier ses r\u00e9sultats du premier semestre et du deuxi\u00e8me trimestre le 27 juillet 2023.<\/p>\n<p><strong>Notes<\/strong><\/p>\n<p align=\"justify\">Tous les chiffres financiers sont exprim\u00e9s en millions d\u2019euros. Sauf indication contraire, les performances publi\u00e9es dans le pr\u00e9sent communiqu\u00e9 couvrent la p\u00e9riode de trois mois courant jusqu&rsquo;au 31 mars 2023 (le premier trimestre ou T1 2023), comparativement \u00e0 la p\u00e9riode de trois mois jusqu&rsquo;au 31 mars 2022 (T1 2022).<\/p>\n<p><strong>Ipsen<\/strong><\/p>\n<p align=\"justify\">Ipsen est une soci\u00e9t\u00e9 biopharmaceutique mondiale de taille moyenne focalis\u00e9e sur la mise au point de m\u00e9dicaments innovants en Oncologie, dans les Maladies Rares et en Neurosciences. Avec un chiffre d\u2019affaires Groupe de 3,0 milliards d\u2019euros pour l\u2019exercice 2022, Ipsen vend des m\u00e9dicaments dans plus de 100 pays. Outre sa strat\u00e9gie d\u2019innovation externe, les efforts d\u2019Ipsen en mati\u00e8re de R&amp;D sont focalis\u00e9s sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur de clusters mondiaux de la recherche biotechnologique ou en sciences de la vie : Paris-Saclay, France ; Oxford, Royaume-Uni ; Cambridge, \u00c9tats-Unis\u00a0; Shanghai, Chine. Ipsen emploie environ 5 400 collaborateurs dans le monde. Ipsen est cot\u00e9 \u00e0 Paris (Euronext\u00a0: IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Le site Internet d\u2019Ipsen est ipsen.com.<\/p>\n<table style=\"border-collapse: collapse;width:763px;border-collapse:collapse\">\n<tr>\n<td style=\"width:406.4px;vertical-align: top\">    <strong>Contacts<\/strong>    <\/td>\n<td style=\"width:248.47px;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:406.4px;vertical-align: top\">    <strong><u>Investisseurs<\/u><\/strong>    <\/td>\n<td style=\"width:248.47px;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:406.4px;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\">    <strong>Craig Marks<\/strong><br \/>Vice-Pr\u00e9sident, Relations Investisseurs<br \/>+44 (0)7584 349 193                    <\/td>\n<td style=\"width:248.47px;vertical-align: top\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:406.4px;text-align: justify;vertical-align: middle;vertical-align: top\">    <strong><u>M\u00e9dias<\/u><\/strong>    <\/td>\n<td style=\"width:248.47px;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:406.4px;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\">    <strong>Amy Wolf<\/strong><br \/>Vice-Pr\u00e9sidente, Strat\u00e9gie de la marque Corporate<br \/>et Communication<br \/>+41 79 576 07 23<\/p>\n<p>                                \u00a0    <\/td>\n<td style=\"width:248.47px;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;text-align: justify;vertical-align: middle;vertical-align: top;text-align: justify;vertical-align: middle\">    <strong>Ioana\u00a0Piscociu<\/strong><br \/>Responsable Senior,<br \/>Global Media Relations<br \/>+33 6 69 09 12 96                            <\/td>\n<\/tr>\n<\/table>\n<p>            <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:50%;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">    <strong>Chiffre d\u2019affaires par aire th\u00e9rapeutique et par produit<\/strong>    <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Une r\u00e9partition g\u00e9ographique du chiffre d\u2019affaires par produit est pr\u00e9sent\u00e9e en annexe.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:19.75%;vertical-align: middle\">    \u00a0<\/p>\n<p>        \u00a0    <\/td>\n<td style=\"width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"width:14.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>6<\/strong><\/sup>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:7.06%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:7.06%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:7.07%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Oncologie<\/strong>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>570,8<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>556,4<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>2,6%<\/strong>    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>1,1%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Somatuline    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    263,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    286,0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -8,0%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -9,8%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Cabometyx    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    130,4    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    98,9    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    31,9%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    31,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Decapeptyl    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    130,0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    129,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,6%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,8%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Onivyde    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    36,9    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    40,1    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -7,9%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -12,3%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Tazverik    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    9,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Autres (Oncologie)    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -54,0%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -53,6%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Neurosciences<\/strong>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>156,4<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>120,2<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>30,2%<\/strong>    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>24,4%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Dysport    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    154,6    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    118,4    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    30,5%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    25,2%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Autres (Neurosciences)    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,8    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,7    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,5%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -18,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Maladies\u00a0Rares<\/strong>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>14,7<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>11,3<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>29,8%<\/strong>    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>29,0%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Bylvay    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    5,0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    NutropinAq<sup>\u00ae<\/sup>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    5,4    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    7,1    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -24,1%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -24,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Increlex<sup>\u00ae<\/sup>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,2    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -0,6%    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -3,2%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.75%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Chiffre d\u2019affaires Groupe<\/strong>    <\/td>\n<td style=\"width:1%;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:1%;border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>741,9<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>687,9<\/strong>    <\/td>\n<td style=\"width:7.06%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>7,8%<\/strong>    <\/td>\n<td style=\"width:7.07%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,7%<\/strong>    <\/td>\n<\/tr>\n<\/table>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt;text-align:justify\"><strong>Somatuline<\/strong><sup><strong>\u00ae<\/strong><\/sup> (lanr\u00e9otide)\u00a0: \u00e9rosion limit\u00e9e des ventes en Am\u00e9rique du Nord de 2,7%<sup>6<\/sup> li\u00e9e \u00e0 des effets n\u00e9gatifs sur les prix aux \u00c9tats-Unis, partiellement compens\u00e9s par un impact favorable refl\u00e9tant la baisse des niveaux de stocks des grossistes au premier trimestre 2022. En Europe, les ventes ont diminu\u00e9 de 25,7%<sup>6<\/sup>, en raison de l&rsquo;arriv\u00e9e du g\u00e9n\u00e9rique du lanr\u00e9otide sur plusieurs march\u00e9s, dont la France, l&rsquo;Espagne et l&rsquo;Italie. Les ventes dans le Reste du Monde ont augment\u00e9 de 7,3%<sup>7<\/sup> gr\u00e2ce \u00e0 de solides performances dans plusieurs zones g\u00e9ographiques, dont l&rsquo;Am\u00e9rique latine.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\"><strong>D\u00e9capeptyl<\/strong>\u00a0: performance impact\u00e9e par la baisse des ventes en Chine, li\u00e9e \u00e0 l&rsquo;augmentation des stocks l&rsquo;an dernier en pr\u00e9vision des mesures de confinement relatives au COVID-19. Cet impact est en partie compens\u00e9 par les gains continus de parts de march\u00e9 dans plusieurs march\u00e9s.<\/li>\n<li style=\"text-align:justify\"><strong>Cabometyx<\/strong> : forte croissance des volumes dans le carcinome du rein dans la plupart des zones g\u00e9ographiques, en tant que monoth\u00e9rapie de deuxi\u00e8me ligne et en tant que traitement de premi\u00e8re ligne en association avec le nivolumab dans un nombre croissant de pays.\n<\/li>\n<li style=\"text-align:justify\"><strong>Onivyde<\/strong> : performance impact\u00e9e par le calendrier des exp\u00e9ditions au partenaire d\u2019Ipsen pour les territoires autres que les \u00c9tats-Unis, en partie compens\u00e9e par une solide croissance aux \u00c9tats-Unis.\n<\/li>\n<li style=\"text-align:justify\"><strong>Tazverik<\/strong>\u00a0: ventes consolid\u00e9es sur la totalit\u00e9 du premier trimestre compte tenu de l&rsquo;acquisition d&rsquo;Epizyme finalis\u00e9e en ao\u00fbt 2022. Croissance des ventes commerciales de 21%<sup>7<\/sup><sup>,<\/sup><sup>8<\/sup> sur un an.\n<\/li>\n<li style=\"text-align:justify\"><strong>Dysport<\/strong>: performance tir\u00e9e par la poursuite de la croissance du march\u00e9 de l&rsquo;esth\u00e9tique, refl\u00e9t\u00e9e par une augmentation des ventes au partenaire d&rsquo;Ipsen, Galderma, et une forte demande sur la plupart des march\u00e9s th\u00e9rapeutiques.\n<\/li>\n<li style=\"text-align:justify\"><strong>Bylvay<\/strong>\u00a0: ventes consolid\u00e9es sur un mois, \u00e0 la suite de la finalisation de l&rsquo;acquisition d&rsquo;Albireo en mars 2023.\n<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:50%;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">    <strong>Chiffre d\u2019affaires par zone g\u00e9ographique<\/strong>    <\/td>\n<\/tr>\n<\/table>\n<p>    <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:19.33%;vertical-align: bottom\">    \u00a0<\/p>\n<p>        \u00a0    <\/td>\n<td style=\"width:0.86%;border-right: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"width:13.55%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0.86%;border-right: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"width:6.77%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"width:6.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>7<\/strong><\/sup>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:0.86%;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:6.77%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:6.78%;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Am\u00e9rique du Nord    <\/td>\n<td style=\"width:0.86%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    244,8    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    226,4    <\/td>\n<td style=\"width:6.77%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    8,1%    <\/td>\n<td style=\"width:6.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    3,6%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Europe<sup>9<\/sup>    <\/td>\n<td style=\"width:0.86%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    296,3    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    304,7    <\/td>\n<td style=\"width:6.77%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -2,7%    <\/td>\n<td style=\"width:6.78%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -2,3%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Reste du Monde    <\/td>\n<td style=\"width:0.86%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    200,8    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    156,9    <\/td>\n<td style=\"width:6.77%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    28,0%    <\/td>\n<td style=\"width:6.78%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    23,2%    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Chiffre d\u2019affaires Groupe<\/strong>    <\/td>\n<td style=\"width:0.86%;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>741,9<\/strong>    <\/td>\n<td style=\"width:8.13%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>687,9<\/strong>    <\/td>\n<td style=\"width:6.77%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>7,8%<\/strong>    <\/td>\n<td style=\"width:6.78%;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,7%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:19.33%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:0.86%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:8.13%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:8.13%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:6.77%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"width:6.78%;border-top: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<\/tr>\n<\/table>\n<ul type=\"disc\">\n<li style=\"text-align:justify\"><strong>Am\u00e9rique du Nord<\/strong> : les ventes ont augment\u00e9 de 3,6%<sup>7<\/sup>, tir\u00e9es par une solide performance d&rsquo;Onivyde et la contribution des m\u00e9dicaments r\u00e9cemment acquis Tazverik et Bylvay, partiellement compens\u00e9s par la baisse des ventes de Dysport \u00e0 Galderma en m\u00e9decine esth\u00e9tique, ainsi que par l&rsquo;\u00e9rosion progressive des ventes de Somatuline.\n<\/li>\n<li style=\"text-align:justify\"><strong>Europe<\/strong>\u00a0: ventes en baisse de 2,3%<sup>7<\/sup>, principalement tir\u00e9es par la performance de Somatuline li\u00e9e \u00e0 l&rsquo;arriv\u00e9e du g\u00e9n\u00e9rique du lanr\u00e9otide et par la baisse des ventes d&rsquo;Onivyde au partenaire d\u2019Ipsen pour les territoires autres que les \u00c9tats-Unis, compens\u00e9e par la forte croissance de Cabometyx et de Dysport sur les march\u00e9s th\u00e9rapeutiques et esth\u00e9tiques.\n<\/li>\n<li style=\"text-align:justify\"><strong>Reste du monde<\/strong> : les ventes ont augment\u00e9 de 23,2%<sup>7<\/sup>, port\u00e9es par les solides performances de Cabometyx et de Dysport, principalement en Am\u00e9rique latine et dans la r\u00e9gion Moyen-Orient et Afrique du Nord.\n<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:50%;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">    <strong>Annexe : r\u00e9partition g\u00e9ographique du chiffre d\u2019affaires par produit<\/strong>    <\/td>\n<\/tr>\n<\/table>\n<p>    <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"3\" style=\"vertical-align: middle\">    \u00a0<\/p>\n<p>        \u00a0<\/p>\n<p>        \u00a0    <\/td>\n<td style=\"border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td colspan=\"4\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Total<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td colspan=\"4\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Am\u00e9rique du Nord<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td colspan=\"4\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Europe<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td colspan=\"4\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Reste du Monde<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2023<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>T1 2022<\/strong>    <\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>% variation<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>10<\/strong><\/sup>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>10<\/strong><\/sup>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>10<\/strong><\/sup>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>(M\u20ac)<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>R\u00e9alis\u00e9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">    <strong>TCC<\/strong><sup><strong>10<\/strong><\/sup>    <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:16%;width:16%;min-width:16%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"max-width:5%;width:5%;min-width:5%;border-top: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Oncologie<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>570,8<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>556,4<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>2,6%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>1,1%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>202,9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>184,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>10,1%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,7%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>239,8<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>267,9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-10,5%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-10,0%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>128,0<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>104,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>22,8%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>19,9%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     Somatuline    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    263,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    286,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -8,0%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -9,8%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    153,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    151,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,4%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -2,7%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    77,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    105,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -26,7%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -25,7%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    32,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    29,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    10,9%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    7,3%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     D\u00e9capeptyl    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    130,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    129,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,6%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,8%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    73,3    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    73,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -0,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,1%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    56,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    55,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,2%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,6%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Cabometyx    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    130,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    98,9    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    31,9%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    31,0%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,8%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    6,9%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    87,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    75,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    15,7%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    16,3%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    39,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    19,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    99,1%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    85,8%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Onivyde    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    36,9    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    40,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -7,9%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -12,3%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    35,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    28,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    24,7%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    19,1%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    11,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -89,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -90,9%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;     <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Tazverik    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    9,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    9,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a     <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Autres Produits d\u2019Oncologie    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,2    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -54,0%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -53,6%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    50,8%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    53,8%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,9    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -55,9%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -55,8%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a.    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Neurosciences<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>156,4<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>120,2<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>30,2%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>24,4%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>36,5<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>39,5<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-7,5%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-11,9%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>47,7<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>28,4<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>68,1%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>69,6%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>72,2<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>52,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>38,0%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>29,0%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     Dysport    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    154,6    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    118,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    30,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    25,2%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    36,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    39,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -7,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -11,9%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    47,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    28,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    68,1%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    69,6%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    70,3    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    50,5    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    39.1%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    31,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Autres (Neurosciences)    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,8    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -18,0%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,8    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    1,7    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    4,5%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -18,0%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Maladies\u00a0Rares <\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>14,7<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>11,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>29,8%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>29,0%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>2,6<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>n\/a<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>95,6%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>8,7<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>8,4<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>4,0%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>4,2%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>0,6<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>0,3<\/strong>    <\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: middle;text-align: left;padding-left: 30.0px;vertical-align: middle;text-align: left;padding-left: 30.0px;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>n\/a<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>n\/a<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    Bylvay    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    5,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    3,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    2,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    n\/a    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     NutropinAq    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    5,4    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    7,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -24,1%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -24,0%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    &#8211;    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    5,1    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    6,8    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -25,0%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -24,9%    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,3    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    0,3    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -2,3%    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    -1,5%    <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>Chiffre d\u2019affaires Groupe<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>741,9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>687,9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>7,8%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>5,7%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>244,8<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>226,4<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>8,1%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>3,6%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>296,3<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>304,7<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-2,7%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>-2,3%<\/strong>    <\/td>\n<td style=\"border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>200,8<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>156,9<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>28,0%<\/strong>    <\/td>\n<td style=\"text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">    <strong>23,2%<\/strong>    <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<td style=\"vertical-align: middle\">    \u00a0    <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Avertissement IPSEN<\/strong><br \/>Les \u00e9nonc\u00e9s prospectifs et objectifs contenus dans cette pr\u00e9sentation sont bas\u00e9s sur la strat\u00e9gie de gestion, les opinions et les hypoth\u00e8ses actuelles d\u2019Ipsen. Ces projections et objectifs peuvent \u00eatre affect\u00e9s par des risques connus ou non et des impr\u00e9vus susceptibles d\u2019entra\u00eener une divergence significative entre les r\u00e9sultats, performances ou \u00e9v\u00e9nements effectifs et ceux envisag\u00e9s dans ce communiqu\u00e9. De tels risques et impr\u00e9vus pourraient affecter la capacit\u00e9 d\u2019Ipsen \u00e0 atteindre ses objectifs financiers, lesquels reposent sur des hypoth\u00e8ses raisonnables quant aux conditions macro\u00e9conomiques \u00e0 venir formul\u00e9es d\u2019apr\u00e8s les informations disponibles \u00e0 ce jour. L&rsquo;utilisation des termes \u00ab croit \u00bb, \u00ab envisage \u00bb et \u00ab pr\u00e9voit \u00bb ou d&rsquo;expressions similaires a pour but d&rsquo;identifier des \u00e9nonc\u00e9s prospectifs, notamment les attentes d\u2019Ipsen quant \u00e0 des \u00e9v\u00e9nements futurs tels que les soumissions et d\u00e9cisions r\u00e9glementaires. De plus, les objectifs mentionn\u00e9s dans ce document sont \u00e9tablis sans tenir compte d\u2019\u00e9ventuelles op\u00e9rations futures de croissance externe qui pourraient venir modifier tous ces param\u00e8tres. Ces objectifs sont notamment fond\u00e9s sur des donn\u00e9es et hypoth\u00e8ses consid\u00e9r\u00e9es comme raisonnables par Ipsen. Ils prennent en compte des circonstances ou des faits susceptibles de se produire \u00e0 l\u2019avenir, et non pas exclusivement des donn\u00e9es historiques. Les r\u00e9sultats r\u00e9els pourraient s\u2019av\u00e9rer substantiellement diff\u00e9rents de ces objectifs compte tenu de la mat\u00e9rialisation de certains risques ou incertitudes, notamment le fait qu\u2019un nouveau produit qui semblait prometteur au cours d\u2019une phase pr\u00e9paratoire de d\u00e9veloppement ou \u00e0 la suite d\u2019essais cliniques puisse ne jamais \u00eatre commercialis\u00e9 ou ne pas atteindre ses objectifs commerciaux, entre autres pour des raisons r\u00e9glementaires ou concurrentielles. Ipsen doit ou peut avoir \u00e0 faire face \u00e0 la concurrence de produits g\u00e9n\u00e9riques, qui pourrait se traduire par des pertes de parts de march\u00e9. En outre, le processus de recherche et de d\u00e9veloppement comprend plusieurs \u00e9tapes et, lors de chaque \u00e9tape, le risque est important qu\u2019Ipsen ne parvienne pas \u00e0 atteindre ses objectifs et en soit conduit \u00e0 abandonner ses efforts sur un produit dans lequel il a investi des sommes consid\u00e9rables. Aussi, Ipsen ne peut \u00eatre certain que des r\u00e9sultats favorables obtenus lors des essais pr\u00e9cliniques seront confirm\u00e9s ult\u00e9rieurement lors des essais cliniques ou que les r\u00e9sultats de ceux-ci seront suffisants pour d\u00e9montrer le caract\u00e8re s\u00fbr et efficace du produit concern\u00e9. Il ne saurait \u00eatre garanti qu&rsquo;un m\u00e9dicament recevra les homologations n\u00e9cessaires ou qu&rsquo;il rencontre un succ\u00e8s commercial. Les r\u00e9sultats r\u00e9els pourraient \u00eatre sensiblement diff\u00e9rents de ceux annonc\u00e9s dans les \u00e9nonc\u00e9s prospectifs si les hypoth\u00e8ses sous-jacentes s&rsquo;av\u00e8rent inexactes ou si certains risques ou incertitudes se mat\u00e9rialisent. Les autres risques et incertitudes comprennent, sans toutefois s&rsquo;y limiter, la situation g\u00e9n\u00e9rale du secteur et la concurrence ; les facteurs \u00e9conomiques g\u00e9n\u00e9raux, y compris les fluctuations des taux d&rsquo;int\u00e9r\u00eat et des taux de change ; l&rsquo;incidence de la r\u00e9glementation de l&rsquo;industrie pharmaceutique et de la l\u00e9gislation en mati\u00e8re de sant\u00e9 ; les tendances mondiales vers une plus grande ma\u00eetrise des co\u00fbts de sant\u00e9 ; les avanc\u00e9es technologiques, les nouveaux m\u00e9dicaments et les brevets obtenus par la concurrence ; les probl\u00e8mes inh\u00e9rents au d\u00e9veloppement de nouveaux m\u00e9dicaments, notamment l&rsquo;obtention d&rsquo;une homologation ; la capacit\u00e9 d\u2019Ipsen \u00e0 pr\u00e9voir avec pr\u00e9cision les futures conditions du march\u00e9 ; les difficult\u00e9s ou d\u00e9lais de production ; l&rsquo;instabilit\u00e9 financi\u00e8re de l&rsquo;\u00e9conomie internationale et le risque souverain ; la d\u00e9pendance \u00e0 l&rsquo;\u00e9gard de l&rsquo;efficacit\u00e9 des brevets d\u2019Ipsen et d\u2019autres protections concernant les m\u00e9dicaments novateurs ; et le risque de litiges, notamment des litiges en mati\u00e8re de brevets ou des recours r\u00e9glementaires. Ipsen d\u00e9pend \u00e9galement de tierces parties pour le d\u00e9veloppement et la commercialisation de ses m\u00e9dicaments, ce qui peut donner lieu \u00e0 des redevances substantielles ; en outre ces partenaires pourraient agir de mani\u00e8re \u00e0 nuire aux activit\u00e9s d\u2019Ipsen ainsi qu\u2019\u00e0 ses r\u00e9sultats financiers. Ipsen ne peut \u00eatre certain que ses partenaires tiendront leurs engagements. Ipsen pourrait ne pas \u00eatre en mesure de tirer avantage des accords conclus. Une d\u00e9faillance d\u2019un de ses partenaires pourrait engendrer une baisse impr\u00e9vue de revenus pour Ipsen. De telles situations pourraient avoir un impact n\u00e9gatif sur l\u2019activit\u00e9 d\u2019Ipsen, sa situation financi\u00e8re ou ses r\u00e9sultats. Sous r\u00e9serve des dispositions l\u00e9gales en vigueur, Ipsen ne prend aucun engagement de mettre \u00e0 jour ou de r\u00e9viser les \u00e9nonc\u00e9s prospectifs ou objectifs vis\u00e9s dans le pr\u00e9sent communiqu\u00e9 afin de refl\u00e9ter des changements qui viendraient affecter les \u00e9v\u00e9nements, situations, hypoth\u00e8ses ou circonstances sur lesquels ces \u00e9nonc\u00e9s se fondent. L&rsquo;activit\u00e9 d\u2019Ipsen est soumise \u00e0 des facteurs de risques qui sont d\u00e9crits dans ses documents d&rsquo;information enregistr\u00e9s aupr\u00e8s de l&rsquo;Autorit\u00e9 des march\u00e9s financiers. Les risques et incertitudes pr\u00e9sent\u00e9s ne sont pas les seuls auxquels Ipsen peut \u00eatre confront\u00e9 et le lecteur est invit\u00e9 \u00e0 prendre connaissance du Document d\u2019enregistrement universel 2022 du Groupe disponible sur son site web <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HBRmubDpLfY49y0cmJ69GnaF0PCAgMzIJ-X4GYZ2vOHaRm3b124CAHYX2-hZ1DZG5sNfjfXDWut0JBk2dO8tlA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.ipsen.com\">www.ipsen.com<\/a>.<\/p>\n<hr \/>\n<p align=\"justify\"><sup>1<\/sup> Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente. <br \/><sup>2<\/sup> Le chiffre d\u2019affaires mentionn\u00e9 dans le pr\u00e9sent communiqu\u00e9 est un chiffre d\u2019affaires consolid\u00e9 IFRS non audit\u00e9.<br \/><sup>3<\/sup> Dysport, D\u00e9capeptyl<sup>\u00ae<\/sup> (triptor\u00e9line), Cabometyx et Onivyde<sup>\u00ae<\/sup> (irinot\u00e9can).<br \/><sup>4<\/sup> Les performances de l\u2019activit\u00e9 Sant\u00e9\u00a0Familiale, c\u00e9d\u00e9e en juillet\u00a02022, ont \u00e9t\u00e9 exclues de l\u2019ensemble des commentaires et comparaisons avec les performances ant\u00e9rieures.<br \/><sup>5<\/sup> Le comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP) de l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA), responsable des m\u00e9dicaments \u00e0 usage humain.<br \/><sup>6<\/sup> Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<br \/><sup>7<\/sup> Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<br \/><sup>8<\/sup> Selon les donn\u00e9es report\u00e9es par Epizyme au premier trimestre 2022.<br \/><sup>9<\/sup> Dans le pr\u00e9sent communiqu\u00e9, l\u2019Europe est d\u00e9finie comme les pays membres de l\u2019Union Europ\u00e9enne, le Royaume-Uni, l\u2019Islande, le Liechtenstein, la Norv\u00e8ge et la Suisse.<br \/><sup>10<\/sup> Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hiPD1llS-Q2YAf5mKrrgg32XuuJtG5ywSbiskzqMdvP4Iu_6yoGaqBeY__KLqfFYKdk2uo6a59aLDSkzbWK_3QXQ-iQ6fg3VF-kZ7fyAaNeKi5J6n-Nif_X901a_b0x2wBwwyd6zD16uyIAEbbxIUo1chr4ynL_6UJI3kCmyv99WaH2wZehtr4w6JMY4WWf3QPMkzyq16cw7p21OYuFH--wk9MvcDQ0jTdqwK6kxdRk=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Annonce des ventes r\u00e9alis\u00e9es au premier trimestre 2023\">Annonce des ventes r\u00e9alis\u00e9es au premier trimestre 2023<\/a><\/li>\n<\/ul>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=hiPD1llS-Q2YAf5mKrrgg2knym2ZnDsZ3YAc6bsqBEJWeBaJD81jbOVp2fKlchS48XF6uu8ILAXRzi7S6XOC6gAHikejuLVLfhF9QlbznY81pjR83RyerlNLbt8KaLCM9GZkJQ5Pb0M9mKwg4s0vRdosvHB96nfIN-VV5gdIKIO-KuJoHvvw7C7EexMTFsXVp34of2jJxlYbUL4pzDjUhdqSeAX3bOZ4TP3O2VBspsg=\" title=\"Annonce des ventes r&#233;alis&#233;es au premier trimestre 2023\" rel=\"nofollow noopener\">Annonce des ventes r&#233;alis&#233;es au premier trimestre 2023<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3556,3557],"tags":[],"class_list":["post-63825","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease-fr","category-financial-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#039;exercice 2023 - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#039;exercice 2023 - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/\",\"name\":\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2023-04-27T05:00:00+00:00\",\"dateModified\":\"2023-04-27T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/new-home-page\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#8217;exercice 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","og_url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/","name":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","isPartOf":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage"},"image":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","datePublished":"2023-04-27T05:00:00+00:00","dateModified":"2023-04-27T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MmNjNThhZWQtNzY4MS00ZWMxLThjMWItZmY3ZDg5MmUxNTgyLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023-2655830\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/new-home-page\/"},{"@type":"ListItem","position":2,"name":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#8217;exercice 2023"}]},{"@type":"WebSite","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#website","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#organization","name":"IPSEN","url":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07154612\/Ipsen-logo_168x48-New3.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/63825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/63825\/revisions"}],"wp:attachment":[{"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/media?parent=63825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/categories?post=63825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d14saept1n0koz.cloudfront.net\/fr\/wp-json\/wp\/v2\/tags?post=63825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}